Accessibility Menu
NextCure logo

NextCure(NASDAQ) NXTC

Current Price$4.33
Market Cap$17.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-98%
5 Year-95%
1 Year-11%
1 Month+151%
NextCure last closing stock price
MetricPriceDate
Last closeUSD 4.402026-07-22
NextCure stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-33.63%USD 6.632026-07-15
1 month+151.43%USD 1.752026-06-22
3 month-64.52%USD 12.402026-04-23
Year to date-68.99%USD 14.192025-12-31
1 year-10.57%USD 4.922025-07-22
3 year-79.69%USD 21.662023-07-21
5 year-94.81%USD 84.722021-07-23
Since inception-98.16%USD 238.802019-05-09

NextCure Financials at a Glance

Market Cap

$17.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$54.66M

EPS (TTM)

-$19.07

P/E Ratio

-0.23

Dividend

$0.00

Beta (Volatility)

0.73 (Low)

Price

$4.33

Volume

941

Open

$4.31

Previous Close

$4.40

Daily Range

$4.30 - $4.54

52-Week Range

$1.55 - $15.74

Estimated Earnings Date

Aug 6, 2026

NXTC News

Foolcom-Featured.png

NextCure (NXTC) Q2 Loss Widens 71%

Motley Fool Markets TeamAug 7, 2025
Cancer immunotherapy

NextCure Delays 2 Clinical Trials Due to Coronavirus

Eric VolkmanApr 14, 2020
GettyImages-1139090560

What Does the Future Hold for Nextcure?

David HaenJan 18, 2020
GettyImages-102695956

These Were the 10 Best IPOs of 2019

Taylor CarmichaelDec 26, 2019
589 immune system dude

Is NextCure a Buy?

Maxx ChatskoNov 23, 2019
GettyImages-1144443303

What Happened in the Stock Market Today

Jim CrumlyNov 11, 2019
chalkboard stock down pink

Here's Why NextCure Crashed Today

Maxx ChatskoNov 11, 2019
business-man-launching-gettyimages-836315356

Here's Why NextCure Stock Blew Through the Roof Tuesday

Cory RenauerNov 5, 2019
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NextCure

NextCure, Inc. is a clinical-stage biopharmaceutical company focusing on developing innovative cancer treatments. Its approach targets the immune interactions within the tumor microenvironment to address patients unresponsive to current therapies.

Products and Services

NC410: A LAIR-2 fusion protein designed to enhance T cell infiltration in tumors, showing early promise in ovarian and colorectal cancers.

LNCB74: An antibody-drug conjugate (ADC) targeting B7-H4, aimed at treating various B7-H4 expressing cancers with plans to file an IND application in 2024.

NC525 and NC318: Oncology programs targeting specific proteins in cancers, seeking strategic partners for further development.

NC605 and NC181: Preclinical candidates for non-oncology applications, focusing on chronic bone diseases and Alzheimer's disease, respectively.

What Makes NextCure, Inc. Special

NextCure stands out with its distinctive focus on tumor microenvironment modulation and immune checkpoint therapies, leveraging its proprietary FIND-IO platform to identify new therapeutic targets. This approach aims at uncovering first-in-class treatments for challenging cancer types.

Five Things You Need to Know

NC410 is currently being tested in combination with pembrolizumab, a well-known cancer drug, to increase efficacy in tough-to-treat cancers.

NextCure has paused its internal manufacturing operations to concentrate on its focused pipeline and extend financial runway.

The company is actively seeking partnerships for its oncology programs, namely NC525 and NC318, as well as its non-oncology candidates.

NextCure has formed a co-development agreement with LegoChem Biosciences to advance its ADC programs, starting with LNCB74.

In March 2024, NextCure restructured its operations, reducing its workforce to align resources with prioritization of key programs.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

40

CEO

Michael S. Richman

Website

www.nextcure.com

Headquarters

Beltsville, MD 20705, US

NXTC Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-186.96%

Return on Capital

-143.70%

Return on Assets

-143.94%

Earnings Yield

-4.35%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$17.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.07M

Volume

941

Avg. Volume

2.08M

Financials (TTM)

Gross Profit

-$283.00K

Operating Income

-$56.10M

EBITDA

-$52.85M

Operating Cash Flow

-$49.98M

Capital Expenditure

$0.00

Free Cash Flow

-$49.98M

Cash & ST Invst.

$29.74M

Total Debt

$4.93M

NextCure Performance Analysis

NextCure annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
NextCure sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
NextCure annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -32.327.2%
20232023-12-31USD -27.04-16.3%
20242024-12-31USD -23.88-11.7%
20252025-12-31USD -19.65-17.7%
NextCure sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-140.1%
Q32025-09-3071.5%
Q42025-12-3116.5%
Q12026-03-3130.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$283.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$17.90MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$447.59K

N/A

Employees

40

N/A

Net Income

-$9.80M

+10.8%

EBITDA

-$9.51M

+7.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$29.74M

-46.8%

Total Debt

$4.93M

-15.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$3.88M

-21.0%

Short Term Debt

$1.05M

+12.6%

Return on Assets

-1.44%

N/A

Return on Invested Capital

-1.80%

N/A

Free Cash Flow

-$13.36M

-2.8%

Operating Cash Flow

-$13.36M

-2.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PLURPluri Inc.
$1.90+2.70%
TAOXTAO Synergies Inc.
$3.69+0.54%
JSPRJasper Therapeutics, Inc.
$0.74-1.28%
PSTVPlus Therapeutics, Inc.
$3.74-2.23%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.96-0.27%
AALAmerican Airlines Group
$13.43-0.09%
TQQQProShares Trust - ProShares UltraPro Qqq
$66.54-0.05%
HBANHuntington Bancshares
$17.34-0.05%

Questions About NXTC

What is the current price of NextCure?

NextCure is trading at $4.33 per share.

What is the 52-week range for NextCure?

Over the past 52 weeks, NextCure has traded between $1.55 and $15.74.

How much debt does NextCure have?

As of the most recent reporting period, NextCure reported total debt of $4.93M.

How much cash does NextCure have on hand?

NextCure reported $15.17M in cash and cash equivalents in its most recent financial results.

What is NextCure’s dividend yield?

NextCure does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services